SymBio Pharmaceuticals Limited

October 24, 2012
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Completion of Patient Enrollment for Phase II Clinical Trial of SyB D-0701 in RINV

TOKYO, Japan, October 24, 2012 -- SymBio Pharmaceuticals Limited (JASDAQ: 4582) today announced the completion of patient enrollment of 189 patients for its randomized double-blinded, comparative Phase II clinical trial of SyB D-0701, an antiemetic transdermal patch, for the treatment of cancer patients with radiation-induced nausea and vomiting (RINV).

This treatment is for radiation therapy, in particular, for conventional fractionation to treat cancer patients in combination with various anticancer agent(s), including prior to surgery. Patients can often experience RINV during cycles of radiation treatment that lasts from a couple of days to several weeks, resulting in an interruption of their therapy. SyB D-0701 is a sustained-release transdermal patch containing granisetron, a commercially available 5-HT3 antagonist. Unlike currently available oral and IV formulations, the patch is designed to continuously deliver granisetron through the skin, providing the patient with sustained relief from RINV for at least five days. Beyond RINV, further development of SyB D-0701 is planned for chemotherapy-induced nausea and vomiting (CINV).

“We are pleased with the timely progress of this program and are excited about the potential benefits this therapy can bring to patients who suffer from both radiation- and chemotherapy-induced nausea and vomiting,” said Fuminori Yoshida, CEO of SymBio Pharmaceuticals. “We believe that this small-sized patch will not only improve the quality of life of patients, but also increase overall patient compliance and thus, positive outcome for patients’ lives.”

After completion of administration of the patch to patients and data analyses, SymBio will meet with PMDA to discuss the next steps.

[Please see the following for further information on Glossary and SymBio]

[Contact]
Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

SymBio Pharmaceuticals Limited

Note to Editors

Glossary

Local radiation therapy: when high energy radiation is focused on tumors to destroy cancer cells and suppress cancer cell growth.

Randomized double-blind comparative study: an experimental procedure in which neither the subjects of the experiment nor the persons administering the experiment know the critical aspects of the experiment; a double-blind procedure is used to guard against both experimenter bias and placebo effects.

Placebo: any substance known not to have any pharmacological effect (produces no meaningful changes in an organism, either chemical or biological, etc.) that is made to look like an active ('real') drug

Dose responsive efficacy: a range of doses over which a response occurs.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd, established in March, 2005, by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently Takeda Bio), aspires to be a leading commercial stage specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main focus in the areas of oncology, hematology and autoimmune disease. The company's underlying corporate mission is "delivering hope to patients in need". SymBio's lead drug candidate, TREAKISYM® (bendamustine hydrochloride), has been successfully developed and launched in Japan for refractory/relapsed indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. The company is also actively developing bendamustine in several Phase II trials: frontline indolent NHL, refractory/relapsed aggressive NHL (Phase II completed), and refractory/relapsed multiple myeloma in Japan. The product has been launched in Hong Kong, Singapore, Korea and Taiwan. For additional information, please visit our homepage at http://www.symbiopharma.com.